Menu Back toBiosimilar-Interchangeability-A-Global-Perspective

DIA 2018 Global Annual Meeting

Biosimilar Interchangeability: A Global Perspective

    Session Chair(s)
      Nielsen  Hobbs

      Nielsen Hobbs

      • Editor
      • The Pink Sheet, United States
    Biosimilars are the next big thing in cost-saving – that's been the promise for a while now, but why aren't we there yet? This session will discuss the successes and stumbles so far and gain insight on stimulating market access for interchangeable biosimilars.
    Learning Objective : Describe the various approaches regulators and payors in different countries have used to encourage the uptake of biosimilars; Compare the success of various education efforts for biosimilars; Identify how to plan strategies to address and take advantage of the specific market conditions for biosimilars in different countries; Analyze the incentives offered to sponsors to develop interchangeable biosimilars.
      Steinar  Madsen, MD

      Regulatory Perspective

      Steinar Madsen, MD

      • Medical Director
      • Norwegian Medicines Agency, Norway
      Molly  Burich, MPH


      Molly Burich, MPH

      • Government Affairs - Biosimilars
      • Boehringer Ingelheim, United States
      Chad  Pettit, MBA


      Chad Pettit, MBA

      • Executive Director, Value and Access, Biosimilars
      • Amgen Inc., United States